Analytical Data
-
Gene name
F17a-A
- Application
-
Alternative Names
F17a-A；C19orf27；FAM108A1；Alpha/beta hydrolase domain-containing Protein 17A
-
Species
E.coli
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P11312
-
Expression Region
22-180aa
-
AA Sequence
YDGKITFNGKVVDQTCSVTTESKNLTVKLPTVSANSLASSGKVVGLTPFTILLEGCNTPAVTGAQNVNAYFEPNANTDYTTGNLTNTASSGASNVQIQLLNADGVKAIKLGQAAAAQSVDTVAINDANVTLRYNAQYYATGVATAGDVTSTVNYTIAYQ
-
Molecular Weight
32.4 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
F17a-A is a recombinant protein that has attracted significant research interest due to its potential applications in biotechnology and medicine. This protein, derived from the F17a gene, is known for its ability to bind to specific receptors, influencing various biological processes. Studies have indicated that F17a-A may play a crucial role in modulating immune responses, making it a candidate for therapeutic interventions in autoimmune diseases and infections. Furthermore, its structural characteristics and functional properties make it a valuable target for engineering novel biopharmaceuticals. The recombinant production of F17a-A allows for large-scale synthesis, enabling comprehensive studies into its mechanism of action and efficacy. Researchers are exploring its potential as an adjuvant in vaccine formulations and as a diagnostic tool, particularly in understanding immune system dynamics. The accumulation of data around F17a-A could pave the way for innovative treatments and enhance our understanding of protein interactions in cellular pathways, underscoring its importance in both fundamental research and practical applications in health sciences. As interest in personalized medicine and targeted therapies grows, F17a-A's unique properties position it as a promising candidate for future studies aimed at developing more effective health interventions.
